EGFR and ovarian carcinoma: Moreover, although many studies have employed free melittin in vitro, the observed synergies with EGFR inhibitors such as erlotinib and gefitinib in NSCLC cells [89,90] and with cisplatin in resistant ovarian cancer cells [81] support the rationale for developing nanoparticle-based co-delivery systems for these combinations.